Herbs (Global Traditional) · European
Butterbur (Petasites hybridus) (Petasites hybridus)
Strong Evidencebotanical
Hermetica Superfood Encyclopedia
Butterbur (Petasites hybridus) is a perennial plant whose PA-free root extracts contain petasins as primary bioactive compounds. These compounds inhibit NF-κB signaling pathways to provide anti-inflammatory and spasmolytic effects.
Butterbur (Petasites hybridus) is a perennial herbaceous plant native to Europe and parts of Asia, with extracts primarily sourced from its rhizomes and roots. The plant material is processed via solvent extraction methods using isopropanol-glycerol mixtures followed by petroleum ether partitioning to yield extracts with 60-75% petasin content while removing toxic pyrrolizidine alkaloids.
The available research lacks human clinical trials, RCTs, or meta-analyses for butterbur. All evidence comes from preclinical studies using PA-free extracts standardized to ≥15% petasins, showing effects on oxidative stress and NF-κB biomarkers, but without human trial data or PubMed PMIDs provided.
No clinically studied dosage ranges are available from human trials. Preclinical studies used powdered extracts standardized to ≥15% petasins from rhizomes, but specific dosing for humans has not been established. Consult a healthcare provider before starting any new supplement.
Butterbur (Petasites hybridus) root/rhizome contains negligible macronutrients in therapeutic extract form. Key bioactive compounds include: Sesquiterpenes (primary actives) — petasin and isopetasin collectively comprising 0.1–0.4% of raw root dry weight, concentrated to ≥15% petasins in standardized pharmaceutical extracts (e.g., Ze 339, Petadolex). Pyrrolizidine alkaloids (PAs) — present in raw plant at variable but potentially hepatotoxic levels (senkirkine, integerrimine); PA-free extracts are processed via CO2 supercritical extraction to reduce PAs to <0.1 ppm (below detection thresholds). Polyphenols — caffeic acid esters (e.g., petasitenine-related phenolics) present in trace amounts. Flavonoids — quercetin and kaempferol glycosides detected at low concentrations (<0.05% dry weight). Inulin-type fructans — present in raw rhizome as storage carbohydrates (~5–15% dry weight), though largely absent in concentrated extracts. Essential oils — trace volatile sesquiterpene fractions (<0.1%). Fiber content in raw root is moderate (~8–12% dry weight) but irrelevant in extract form. Vitamins and minerals are negligible and not therapeutically significant. Bioavailability notes: Petasin and isopetasin exhibit moderate oral bioavailability with Tmax ~1–2 hours post-ingestion of standardized extract; lipophilic nature of sesquiterpenes suggests absorption enhanced with dietary fat; PA-free supercritical CO2 extraction preserves petasin content while eliminating hepatotoxic alkaloids, making the standardized extract the only form with an established safety profile for human use.
Petasins, the primary bioactive compounds in butterbur, inhibit nuclear factor-κB (NF-κB) signaling pathways, reducing inflammatory mediator production. The standardized extracts also demonstrate spasmolytic activity by modulating calcium channels in smooth muscle tissue. Additionally, butterbur compounds reduce oxidative stress through antioxidant enzyme pathway activation.
Current evidence for butterbur consists primarily of preclinical studies examining PA-free root extracts standardized to ≥15% petasins. Bulgarian standardized root extracts have shown measurable decreases in oxidative stress biomarkers via ELISA testing in laboratory models. NF-κB biomarker reduction has been documented in preliminary animal studies, though human clinical data remains limited. The evidence strength is considered preliminary pending larger controlled human trials.
Raw butterbur contains potentially hepatotoxic pyrrolizidine alkaloids (PAs), making PA-free extracts essential for safety. Common side effects may include digestive upset, headache, and fatigue in sensitive individuals. Butterbur may interact with anticoagulant medications due to potential blood-thinning effects. Pregnant and breastfeeding women should avoid butterbur due to insufficient safety data.
